Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05426629
Other study ID # DERM-2021-30436
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 14, 2022
Est. completion date April 21, 2025

Study information

Verified date April 2024
Source University of Minnesota
Contact Irmina Wallander
Phone 612-624-5721
Email dermresearch@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be focused on evaluating the use of hydradermabrasion on the scalp. The study aims to assess the effect of this treatment on scalp health and hair growth.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 21, 2025
Est. primary completion date April 21, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participants who can give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA Authorization - Participants who have androgenetic alopecia - Healthy men and women, ages 18 - 65 years of age - Participants who understand the study and can follow study instructions and are willing to attend the required study visits - Participants who agree to be photographed for research purposes and their identity may not be concealed in these photographs. - Participants who agree to continue their same treatment they are on at the baseline visit for androgenetic alopecia, for the entire duration of the study without plans to stop, change or add additional treatments. - Participants who agree to use the same shampoo for the duration of the study Exclusion Criteria: - Participants who have not had a change to hair loss treatment for 4 months prior to study enrollment - Participants who have an active or known skin inflammation or infection within the treatment area. - Participants who have an active or known acute skin allergies - Participants who have any other scalp conditions including eczema, psoriasis, infection, or scars within the treatment area - Participants of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy, or bilateral oophorectomy. - Participants who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy. - Immunosuppression - Participants who are HIV+ / Hepatitis B + / Hepatitis C+ - Participants who have been diagnosed or have a known history of any hematopathology disorders - Participants who have been diagnosed or have a known history of haemostasis disorders - Participants who have been diagnosed or have a known history of an autoimmune diseases - Participants who are undergoing chemotherapy - Participants with a history of any skin cancer on the scalp - Participants who have had skin biopsy or procedure on scalp in last month - Participants who have an implantable devices such as a deep brain stimulator in or other implantable device on or near treatment area - Non-English speakers

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Venus Glow
The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline. Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation. The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore.

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Scalp Health- Erythema Primary endpoints will be changes in the Erythema score from baseline to Visit 8. Erythema score is a scale from 0 to 4. Assessed at Visit 8
Primary Scalp Health- ASFS Primary endpoints will be changes in the Adherent Scalp Flaking Score (ASFS) from baseline to Visit 8. ASFS is a scale 0 to 10. Assessed at Visit 8
Primary Scalp Health- Folliculitis Primary endpoints will be changes in the folliculitis score from baseline to Visit 8. Foliculitis score is a scale from 0 to 3. Assessed at Visit 8
Primary Hair Changes HairMetrix scale evaluates degree of improvement hair density, total hair count per sq cm and patient sensory assessment of scalp and hair from baseline to after each treatment and the follow up visit. The global assessment scales are a scale from 0 to 3. Assessed at Visit 8
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A